Collegium Pharmaceutical, Inc. (NASDAQ:COLL) was upgraded by stock analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday.

A number of other equities analysts also recently weighed in on COLL. Zacks Investment Research downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Tuesday, March 14th. Jefferies Group LLC set a $24.00 price target on shares of Collegium Pharmaceutical and gave the stock a “buy” rating in a report on Saturday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target (down previously from $30.00) on shares of Collegium Pharmaceutical in a report on Wednesday, April 19th. Finally, Janney Montgomery Scott reaffirmed a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $22.83.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL) traded up 7.63% during mid-day trading on Thursday, reaching $12.84. The company’s stock had a trading volume of 1,581,872 shares. Collegium Pharmaceutical has a 52-week low of $7.37 and a 52-week high of $20.55. The firm has a 50 day moving average price of $9.32 and a 200 day moving average price of $12.90. The company’s market cap is $378.24 million.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Wednesday, May 10th. The specialty pharmaceutical company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.19. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $3.55 million. Equities research analysts anticipate that Collegium Pharmaceutical will post ($3.07) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/24/collegium-pharmaceutical-inc-coll-upgraded-to-sell-at-valuengine.html.

In related news, insider Paul Brannelly purchased 10,000 shares of the stock in a transaction that occurred on Friday, May 12th. The shares were bought at an average price of $9.18 per share, with a total value of $91,800.00. Following the acquisition, the insider now owns 110,227 shares of the company’s stock, valued at approximately $1,011,883.86. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 25.76% of the company’s stock.

Several large investors have recently bought and sold shares of COLL. Pier Capital LLC boosted its stake in Collegium Pharmaceutical by 11.1% in the first quarter. Pier Capital LLC now owns 366,064 shares of the specialty pharmaceutical company’s stock worth $3,683,000 after buying an additional 36,435 shares during the period. Trexquant Investment LP bought a new stake in Collegium Pharmaceutical during the first quarter worth approximately $259,000. Bank of New York Mellon Corp boosted its stake in Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the period. Tocqueville Asset Management L.P. boosted its stake in Collegium Pharmaceutical by 38.5% in the first quarter. Tocqueville Asset Management L.P. now owns 108,000 shares of the specialty pharmaceutical company’s stock worth $1,086,000 after buying an additional 30,000 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in Collegium Pharmaceutical by 404.1% in the first quarter. Wells Fargo & Company MN now owns 86,776 shares of the specialty pharmaceutical company’s stock worth $873,000 after buying an additional 69,563 shares during the period. 82.30% of the stock is currently owned by institutional investors.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.